Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Flunarizine versus metoprolol in migraine prophylaxis : a double-blind, randomized parallel group study of efficacy and tolerability. / Sørensen, P S; Larsen, B H; Rasmussen, M J; Kinge, E; Alslev, T; Nøhr, P; Pedersen, K K; Schrøder, P; Lademann, A; Iversen, Helle Klingenberg.

In: Headache Online, Vol. 31, No. 10, 11.1991, p. 650-7.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Sørensen, PS, Larsen, BH, Rasmussen, MJ, Kinge, E, Alslev, T, Nøhr, P, Pedersen, KK, Schrøder, P, Lademann, A & Iversen, HK 1991, 'Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability', Headache Online, vol. 31, no. 10, pp. 650-7.

APA

Sørensen, P. S., Larsen, B. H., Rasmussen, M. J., Kinge, E., Alslev, T., Nøhr, P., Pedersen, K. K., Schrøder, P., Lademann, A., & Iversen, H. K. (1991). Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache Online, 31(10), 650-7.

Vancouver

Sørensen PS, Larsen BH, Rasmussen MJ, Kinge E, Alslev T, Nøhr P et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache Online. 1991 Nov;31(10):650-7.

Author

Sørensen, P S ; Larsen, B H ; Rasmussen, M J ; Kinge, E ; Alslev, T ; Nøhr, P ; Pedersen, K K ; Schrøder, P ; Lademann, A ; Iversen, Helle Klingenberg. / Flunarizine versus metoprolol in migraine prophylaxis : a double-blind, randomized parallel group study of efficacy and tolerability. In: Headache Online. 1991 ; Vol. 31, No. 10. pp. 650-7.

Bibtex

@article{6c474f42ed95450288dd4cdf6a78100f,
title = "Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability",
abstract = "The prophylactic effect of flunarizine and metoprolol was studied in a multi-center randomized, double-blind trial of 149 patients with migraine with or without aura. After a 4-week placebo run-in period, patients were randomly allocated to treatment with flunarizine 10 mg daily or metoprolol 200 mg daily for 16 weeks (parallel group design). Both drugs reduced the number of migraine days per month by 37% (95% confidence interval 21-53%) compared with the placebo run-in period. All efficacy parameters were significantly reduced by both drugs and no significant difference was found between the two drugs at any time of the treatment period. However, calculation of the 95% confidence limits showed that each drug may have a superiority of more than 100% on a single main effect parameter. The most common adverse experiences were day-time sedation (both drugs) and weight gain (flunarizine). Depression was the most serious side-effect occurring in 8% on flunarizine and 3% on metoprolol. We conclude that both drugs are effective in the prevention of migraine attacks but a higher number of dropouts occurred on flunarizine because of depression or weight gain.",
keywords = "Adult, Double-Blind Method, Female, Flunarizine, Humans, Male, Metoprolol, Middle Aged, Migraine Disorders",
author = "S{\o}rensen, {P S} and Larsen, {B H} and Rasmussen, {M J} and E Kinge and T Alslev and P N{\o}hr and Pedersen, {K K} and P Schr{\o}der and A Lademann and Iversen, {Helle Klingenberg}",
year = "1991",
month = nov,
language = "English",
volume = "31",
pages = "650--7",
journal = "Headache Online",
issn = "1526-4610",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Flunarizine versus metoprolol in migraine prophylaxis

T2 - a double-blind, randomized parallel group study of efficacy and tolerability

AU - Sørensen, P S

AU - Larsen, B H

AU - Rasmussen, M J

AU - Kinge, E

AU - Alslev, T

AU - Nøhr, P

AU - Pedersen, K K

AU - Schrøder, P

AU - Lademann, A

AU - Iversen, Helle Klingenberg

PY - 1991/11

Y1 - 1991/11

N2 - The prophylactic effect of flunarizine and metoprolol was studied in a multi-center randomized, double-blind trial of 149 patients with migraine with or without aura. After a 4-week placebo run-in period, patients were randomly allocated to treatment with flunarizine 10 mg daily or metoprolol 200 mg daily for 16 weeks (parallel group design). Both drugs reduced the number of migraine days per month by 37% (95% confidence interval 21-53%) compared with the placebo run-in period. All efficacy parameters were significantly reduced by both drugs and no significant difference was found between the two drugs at any time of the treatment period. However, calculation of the 95% confidence limits showed that each drug may have a superiority of more than 100% on a single main effect parameter. The most common adverse experiences were day-time sedation (both drugs) and weight gain (flunarizine). Depression was the most serious side-effect occurring in 8% on flunarizine and 3% on metoprolol. We conclude that both drugs are effective in the prevention of migraine attacks but a higher number of dropouts occurred on flunarizine because of depression or weight gain.

AB - The prophylactic effect of flunarizine and metoprolol was studied in a multi-center randomized, double-blind trial of 149 patients with migraine with or without aura. After a 4-week placebo run-in period, patients were randomly allocated to treatment with flunarizine 10 mg daily or metoprolol 200 mg daily for 16 weeks (parallel group design). Both drugs reduced the number of migraine days per month by 37% (95% confidence interval 21-53%) compared with the placebo run-in period. All efficacy parameters were significantly reduced by both drugs and no significant difference was found between the two drugs at any time of the treatment period. However, calculation of the 95% confidence limits showed that each drug may have a superiority of more than 100% on a single main effect parameter. The most common adverse experiences were day-time sedation (both drugs) and weight gain (flunarizine). Depression was the most serious side-effect occurring in 8% on flunarizine and 3% on metoprolol. We conclude that both drugs are effective in the prevention of migraine attacks but a higher number of dropouts occurred on flunarizine because of depression or weight gain.

KW - Adult

KW - Double-Blind Method

KW - Female

KW - Flunarizine

KW - Humans

KW - Male

KW - Metoprolol

KW - Middle Aged

KW - Migraine Disorders

M3 - Journal article

C2 - 1769820

VL - 31

SP - 650

EP - 657

JO - Headache Online

JF - Headache Online

SN - 1526-4610

IS - 10

ER -

ID: 128985626